Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
Public ClinicalTrials.gov record NCT00530855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects With Partial-onset Seizures
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the conversion to monotherapy trial (SP902).
Study identification
- NCT ID
- NCT00530855
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 322 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2008 (Type not available)
- Primary completion
- Dec 2014 (Actual)
- Completion
- Dec 2014 (Actual)
- Last update posted
- Jul 18, 2018
2008 – 2014
United States locations
- U.S. sites
- 77
- U.S. states
- 34
- U.S. cities
- 69
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 048 | Alabaster | Alabama | — | — |
| 010 | Birmingham | Alabama | — | — |
| 042 | Northport | Alabama | — | — |
| 009 | Phoenix | Arizona | — | — |
| 014 | Phoenix | Arizona | — | — |
| 151 | Phoenix | Arizona | — | — |
| 103 | Tucson | Arizona | — | — |
| 102 | Jonesboro | Arkansas | — | — |
| 007 | Little Rock | Arkansas | — | — |
| 086 | Little Rock | Arkansas | — | — |
| 120 | La Habra | California | — | — |
| 059 | Los Angeles | California | — | — |
| 021 | Santa Monica | California | — | — |
| 107 | Torrance | California | — | — |
| 060 | Aurora | Colorado | — | — |
| 025 | Fairfield | Connecticut | — | — |
| 094 | Doral | Florida | — | — |
| 108 | Gainesville | Florida | — | — |
| 123 | Miami | Florida | — | — |
| 132 | Miami | Florida | — | — |
| 077 | Orlando | Florida | — | — |
| 049 | Panama City | Florida | — | — |
| 129 | Port Charlotte | Florida | — | — |
| 050 | Sarasota | Florida | — | — |
| 004 | Tallahassee | Florida | — | — |
| 079 | Atlanta | Georgia | — | — |
| 058 | Boise | Idaho | — | — |
| 131 | Hines | Illinois | — | — |
| 146 | Peoria | Illinois | — | — |
| 011 | Springfield | Illinois | — | — |
| 078 | Indianapolis | Indiana | — | — |
| 073 | Ames | Iowa | — | — |
| 124 | Manhattan | Kansas | — | — |
| 023 | Wichita | Kansas | — | — |
| 160 | Wichita | Kansas | — | — |
| 164 | Lexington | Kentucky | — | — |
| 062 | Louisville | Kentucky | — | — |
| 029 | Scarborough | Maine | — | — |
| 020 | Baltimore | Maryland | — | — |
| 034 | Baltimore | Maryland | — | — |
| 065 | Pikesville | Maryland | — | — |
| 137 | Waldorf | Maryland | — | — |
| 041 | Detroit | Michigan | — | — |
| 030 | Golden Valley | Minnesota | — | — |
| 071 | Hattiesburg | Mississippi | — | — |
| 031 | Chesterfield | Missouri | — | — |
| 066 | St Louis | Missouri | — | — |
| 017 | Lebanon | New Hampshire | — | — |
| 067 | Voorhees Township | New Jersey | — | — |
| 036 | Albany | New York | — | — |
| 083 | Buffalo | New York | — | — |
| 069 | Cedarhurst | New York | — | — |
| 027 | New York | New York | — | — |
| 122 | New York | New York | — | — |
| 003 | Asheville | North Carolina | — | — |
| 063 | Durham | North Carolina | — | — |
| 117 | Wilmington | North Carolina | — | — |
| 015 | Cleveland | Ohio | — | — |
| 061 | Columbus | Ohio | — | — |
| 002 | Toledo | Ohio | — | — |
| 147 | Oklahoma City | Oklahoma | — | — |
| 100 | Greensburg | Pennsylvania | — | — |
| 032 | Philadelphia | Pennsylvania | — | — |
| 024 | Beaufort | South Carolina | — | — |
| 114 | Chattanooga | Tennessee | — | — |
| 001 | Nashville | Tennessee | — | — |
| 138 | Austin | Texas | — | — |
| 022 | Dallas | Texas | — | — |
| 046 | El Paso | Texas | — | — |
| 051 | Houston | Texas | — | — |
| 053 | Houston | Texas | — | — |
| 098 | San Antonio | Texas | — | — |
| 136 | Layton | Utah | — | — |
| 161 | Alexandria | Virginia | — | — |
| 016 | Charlottesville | Virginia | — | — |
| 074 | Renton | Washington | — | — |
| 080 | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00530855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2018 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00530855 live on ClinicalTrials.gov.